We are hiring again. This time, we are on the lookout for a new laboratory technician.

Advert in Czech language only.

Get in touch if you are interested and join our Protein Pro Team.

Enantis is going to participate at the Future of protein production summit that takes place online between 8th and 10th March 2022.

https://lnkd.in/dThnfm9Y

We would like to use this opportunity to offer our FGF2-STAB to cultured meat companies and cultured meat media developers as an innovative and highly effective media ingredient. If you are interested in our solution, get in touch.

As a closure of an eventful year, Enantis would like to wish a Merry Christmas and a Happy New Year to all our customers, collaborators, supporters and friends!

In 2021, we have reached many important milestones. We have closed new licensing deals securing a global presence of our products on the stem cell culture market. Moreover, we have manufactured record volumes of FGF2-STAB to supply our exclusive distributor and launched a new product, FGF10-STAB. Also, we have maintained our ISO 9001:2016 certification that assures well-managed quality management system in our company and started to explore new markets for our products

We are really proud of our achievements and hope this is just a start and even greater things will happen in 2022. Thank you for your support.

It’s been a blast! Even though we have not made it into finals, we are really proud and grateful for the opportunity to be a part of the EIT Health Catapult 2021. It has been an amazing experience and importantly, we had a chance to meet other promising biotech companies from all around Europe – AddaxBiosciences, APLEX Bio SideROS , Asylia Diagnostics BV, Bioadhesive Ophthalmics, Finnadvance, Limula, myNEO – Personalised platform for cancer, OmicEra Diagnostics, Onena Medicines Renovos Biologics Limited, ARTHEx Biotech and SolasCure.

Big shout out to the organisers and huge congratulations to the companies selected to proceed to the final round from all three categories – Biotech, Medtech and Digital Health

Onena Medicines, SideROS , SolasCure, ARTHEx Biotech, Asylia Diagnostics BV, Limula, myNEO – Personalised platform for cancer, Leuko, Luminate Medical , ThinkSono, ArthroSave B.V., BeFC Bioenzymatic Fuel Cells FeelTect, ORIXHA, AZmed, Brightlobe, Ebenbuild, Amara Therapeutics, Exheus, Heaxel and mentalis.

Enantis has entered into a global supply agreement with one of the top providers of life science solutions with our innovative FGF10-STAB®. This novel, engineered protein protected by a patent is now entering the research and cell therapy market.

This is the second global supply agreement Enantis has in place. The first one covers the distribution of FGF2-STAB® molecule and we hope the new contract will bring similar business success.

Under the terms of agreement, Enantis will exclusively supply the laboratory reagents provider with FGF10-STAB® to assure worldwide accessibility of this molecule to the scientific community.

A new tool for a design of stable proteins, FireProt-ASR, has been added to Enantis protein engineering portfolio. This software has been developed by Loschmidt Laboratories and Enantis provides licenses to commercial users.

Get in touch at enantis[at]enantis.com if you are interested!

Enantis is still searching for a new CTO/CSO and also for a Senior Scientist to join our team. 

Do you think you have what it takes? Get in touch with us.

CSO/CTO advert here

Senior Scientist advert here

Enantis’ FGF2-STAB® licensed by Defined Bioscience for use in stem cell media

Enantis recently concluded a licensing agreement with US-based company Defined Bioscience for global use of our patented FGF2-STAB® technology, for use alone and in stem cell media formulations.

“Defined Bioscience is excited to offer FGF2-STAB® to its customers,” said Dr. Steven Rees, CEO of Defined Bioscience. “Thermostable, high-functioning growth factors are critical to the stem cell culture industry, and innovations like this will pave the way for cost-effective, next-generation technologies in the space.”

FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using computational methods to improve thermostability of the wild-type sequence of fibroblast growth factor 2 (FGF2-WT or bFGF). While FGF2-WT quickly destabilizes in standard stem cell culture conditions, FGF2-STAB® retains full biological activity even after five days at 37°C, allowing for a more homogenous, undifferentiated stem cell culture, less frequent medium changes, and weekend-free cell culture scheduling.

“With Defined Bioscience, we share the vision of enabling weekend-free cultivations to scientists all over the world. Therefore, we are happy that our key product will be part of the innovative stem cell culture media being developed at Defined Bioscience” says Roman Badik, CEO of Enantis. “The license agreement we just concluded will be beneficial for both our growing businesses”.

Enantis and Qkine sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community

Enantis, a biotechnology spin-off company from Masaryk University, and Qkine, Cambridge University spin-out, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally and develop new product-lines based on the unique biochemical properties of the protein.

FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. This optimised form of the protein does not degrade in culture media leading to a range of applications in enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

“With the licensing of FGF2-STAB®, Qkine is continuing to build its portfolio of the most innovative and highest quality growth factors for stem cell biology” says Dr Catherine Elton, Qkine CEO. “We are delighted to work with the team at Enantis, who share our ambition to drive innovation and provide opportunities for the stem cell sector and emerging fields including cellular agriculture and 3D cell culture.”

FGF2-STAB®, originally published in the scientific literature as FGF2-G3, was developed by Enantis and Masaryk University. The proprietary computational platform was used to explore the structure of the protein and selectively exchange amino-acids in the proteins to enhance thermostability without compromising biological function. The same approach was used successfully by Enantis for other members of this family of proteins that have therapeutic and cosmetic applications.

“To meet the growing demand for our key product, we have decided to partner with Qkine, specialists within their field with a great distribution network at their disposal” says Roman Badik, CEO of Enantis. “This licensing deal will be beneficial for both our dynamic small biotechnology companies and provide future opportunities we will grow together”, he added.

About Enantis

Enantis is a private biotechnology company founded as a spin-off from Masaryk University, Czech Republic. Enantis’ expertise is based on vast experience in protein engineering and state-of-the-art software tools. Our key product, FGF2-STAB®, is a patented thermostable form of basic fibroblast growth factor that can revolutionize stem cell culturing. This protein is 50-times more stable than its native counterpart and has a fully retained biological activity. We have other thermostable growth factors in our pipeline. 

About Qkine

Qkine is a Cambridge, UK-based manufacturer of high purity, animal-free growth factors, cytokines and other complex proteins. Qkine combines proprietary production processes with protein engineering technology to tackle fundamental biological and scale-up challenges for the fast-growing stem cell, organoid, regenerative medicine and cultured meat sectors. Visit qkine.com.